[go: up one dir, main page]

NO20010747D0 - Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff - Google Patents

Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff

Info

Publication number
NO20010747D0
NO20010747D0 NO20010747A NO20010747A NO20010747D0 NO 20010747 D0 NO20010747 D0 NO 20010747D0 NO 20010747 A NO20010747 A NO 20010747A NO 20010747 A NO20010747 A NO 20010747A NO 20010747 D0 NO20010747 D0 NO 20010747D0
Authority
NO
Norway
Prior art keywords
von willebrand
willebrand factor
monoclonal antibody
humanized anti
antithrombotic agent
Prior art date
Application number
NO20010747A
Other languages
English (en)
Other versions
NO20010747L (no
Inventor
Man Sung Co
Maximiliano Vasquez
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of NO20010747D0 publication Critical patent/NO20010747D0/no
Publication of NO20010747L publication Critical patent/NO20010747L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20010747A 1998-08-19 2001-02-14 Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff NO20010747L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/136,315 US6228360B1 (en) 1998-08-19 1998-08-19 Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
PCT/US1999/016724 WO2000010601A1 (en) 1998-08-19 1999-08-19 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody

Publications (2)

Publication Number Publication Date
NO20010747D0 true NO20010747D0 (no) 2001-02-14
NO20010747L NO20010747L (no) 2001-04-03

Family

ID=22472317

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010747A NO20010747L (no) 1998-08-19 2001-02-14 Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff

Country Status (17)

Country Link
US (4) US6228360B1 (no)
EP (1) EP1112085B1 (no)
JP (1) JP4590734B2 (no)
KR (1) KR100693260B1 (no)
CN (1) CN1259972C (no)
AT (1) ATE476989T1 (no)
AU (1) AU766500B2 (no)
BR (1) BR9913084A (no)
CA (1) CA2340466A1 (no)
DE (1) DE69942668D1 (no)
HU (1) HUP0103573A3 (no)
IL (2) IL141158A0 (no)
NO (1) NO20010747L (no)
NZ (1) NZ509536A (no)
RU (1) RU2223785C2 (no)
WO (1) WO2000010601A1 (no)
ZA (1) ZA200100939B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
GB0031448D0 (en) * 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
US8372798B2 (en) * 2001-10-16 2013-02-12 Endo Pharmaceuticals Colorado, Inc. High-concentration protein formulations and method of manufacture
JP2005298336A (ja) * 2002-01-29 2005-10-27 Ajinomoto Co Inc 炎症性疾患治療用薬剤
JPWO2004011030A1 (ja) * 2002-07-29 2005-11-24 味の素株式会社 血小板減少症治療用医薬組成物
EP1527346B1 (en) * 2002-08-07 2011-06-08 Ablynx N.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
KR20070004026A (ko) * 2004-03-15 2007-01-05 비오겐 아이덱 엠에이 아이엔씨. 선택적 스플라이싱을 이용하여 진핵 세포에서 폴리펩티드다량체를 발현하기 위한 방법 및 구축물
RU2271010C2 (ru) * 2004-03-31 2006-02-27 Общество с ограниченной ответственностью "Фирма МонА" Способ иммуноферментного анализа для определения фактора виллебранда, моноклональное антитело к фактору виллебранда (варианты) и штамм гибридных культивируемых клеток животных mus. musculus l. - продуцент моноклональных антител к фактору виллебранда (варианты)
ES2356364T3 (es) * 2004-04-15 2011-04-07 Athera Biotechnologies Ab Anexina v para prevenir la ruptura de la placa.
MX2007002772A (es) * 2004-09-07 2008-03-05 Archemix Corp Aptameros para el factor de von willebrand y su uso como agentes terapeuticos para la enfermedad trombotica.
WO2006046935A1 (en) * 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
ATE473446T1 (de) * 2005-01-14 2010-07-15 Ablynx Nv Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
KR101414438B1 (ko) * 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
WO2009115614A2 (en) * 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010210535B2 (en) * 2009-02-06 2015-12-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102532316B (zh) * 2010-12-24 2014-06-18 神州细胞工程有限公司 一种抗vWF单克隆抗体及其应用
ES2924393T3 (es) * 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
CZ291039B6 (cs) * 1992-02-06 2002-12-11 Schering Corporation Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
AU689090B2 (en) * 1992-12-01 1998-03-26 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
UA37249C2 (uk) * 1993-11-05 2001-05-15 Сентокор Інк. Спосіб інгібування стенозу та/або рестенозу (варіанти), спосіб інгібування рестенозу після проведення операції на коронарній артерії у людини (варіанти), спосіб зниження ймовірності виникнення чи запобігання негострих ішемічних ускладнень при ангіопластиці у людини
US5844093A (en) * 1994-03-17 1998-12-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Anti-EGFR single-chain Fvs and anti-EGFR antibodies
ATE236993T1 (de) * 1994-11-30 2003-04-15 Ajinomoto Kk Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody

Also Published As

Publication number Publication date
JP4590734B2 (ja) 2010-12-01
ATE476989T1 (de) 2010-08-15
AU766500B2 (en) 2003-10-16
KR100693260B1 (ko) 2007-03-13
CN1311691A (zh) 2001-09-05
US6613328B2 (en) 2003-09-02
HUP0103573A3 (en) 2003-09-29
US7311913B2 (en) 2007-12-25
NZ509536A (en) 2002-11-26
US7138116B2 (en) 2006-11-21
ZA200100939B (en) 2001-09-03
JP2002523379A (ja) 2002-07-30
US6228360B1 (en) 2001-05-08
WO2000010601A1 (en) 2000-03-02
IL141158A0 (en) 2002-02-10
US20030180293A1 (en) 2003-09-25
DE69942668D1 (de) 2010-09-23
KR20010072749A (ko) 2001-07-31
RU2223785C2 (ru) 2004-02-20
AU5668099A (en) 2000-03-14
EP1112085A4 (en) 2002-11-20
HUP0103573A2 (hu) 2002-01-28
IL141158A (en) 2006-04-10
CA2340466A1 (en) 2000-03-02
NO20010747L (no) 2001-04-03
EP1112085A1 (en) 2001-07-04
EP1112085B1 (en) 2010-08-11
US20050197494A1 (en) 2005-09-08
US20030064068A1 (en) 2003-04-03
CN1259972C (zh) 2006-06-21
BR9913084A (pt) 2001-05-08

Similar Documents

Publication Publication Date Title
NO20010747D0 (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
DK0724456T3 (da) CD40-Antistoffer
RS53984B1 (en) IP-10 ANTIBODIES AND THEIR USES
NO2006008I1 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
PT973550E (pt) Anticorpos antagonistas anti-integrina avb3
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ATE218387T1 (de) Antikörperreinigung
IS2508B (is) Mótefni gegn ED-B hneppinu í fíbrónektíni, smíði þeirra og notkanir
EE201200006A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
EE200100336A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
HRP20000714B1 (en) NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
FI963004A7 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE3580382D1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
NO20004251D0 (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
BR1100555B1 (pt) anticorpos monoclonais humanizados.
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk